Eisai Co. Ltd. has exercised its right to opt-in on Biogen Inc.'s Phase III Alzheimer's disease candidate aducanumab with terms that appear favorable to Biogen. The companies announced the expansion of their existing development and commercialization deal Oct. 23.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?